Treatment of hepatitis C virus genotype 3 infection with direct-acting antiviral agents

Hepatitis C virus (HCV) genotype 3 is responsible for 30.1% of chronic hepatitis C infection cases worldwide. In the era of direct-acting antivirals, these patients have become one of the most challenging to treat, due to fewer effective drug options, higher risk of developing cirrhosis and hepatoce...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Braz J Med Biol Res
Hlavní autoři: Zanaga, L.P., Miotto, N., Mendes, L.C., Stucchi, R.S.B., Vigani, A.G.
Médium: Artigo
Jazyk:Inglês
Vydáno: Associação Brasileira de Divulgação Científica 2016
Témata:
Reviews
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5089232/
https://ncbi.nlm.nih.gov/pubmed/27783808
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1590/1414-431X20165504
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky